List of Changzhou second bargaining shortlisted

Source: on July 14, 2017-7-15, the notice of Jiangsu Province on publishing the shortlisted products of 2016 emergency (emergency) rescue and non patent medical institutions of women and children's specialty in Changzhou City, with 690 shortlisted products and shortlisted prices attached It is noteworthy that compared with the provincial bidding prices in Jiangsu Province, 147 of them haggle over 50%, accounting for 21% of the total, while the decline rate is more than 80% everywhere Jiangsu Province is a major pharmaceutical Province in China, and also one of the provinces designated by the State Council in 2015 to carry out the pilot work of comprehensive medical reform It has attracted industry attention in breaking the mechanism of drug-based medical care and implementing zero margin sales of drugs Especially in the process of reforming the centralized purchase of drugs in public hospitals, every movement is pulling the nerve of the industry According to the notice, "after our city publishes the shortlisted products and prices, we will make irregular price adjustments with reference to the confirmed transaction prices of the same products in other municipalities under our province If there is any lower than the transaction prices in our city, we will take the lowest price as the transaction prices of our products." In this regard, the industry's concern: the lowest bid rules will cause drug quality and safety problems Moreover, the large-scale diving price reduction is difficult to avoid malicious competition from some enterprises, which may also affect the hospital's drug supply Diving price reduction from 40 yuan to 1.79 yuan in the shortlist, the price reduction range of some products is unbelievable, taking Qingkailing injection as an example, two manufacturers reduced about 95% The price of Ji'an Yisheng Pharmaceutical Co., Ltd in Jilin Province has been reduced to 0.5 yuan from 8.8 yuan at the provincial level, and that of another Shennong Pharmaceutical Co., Ltd in Henan Province has been reduced to 1.79 yuan from 40 yuan, a drop of more than 96% The more exaggerated price cut caused concern in the industry The first is why the price reduction is so large, which challenges the production cost of pharmaceutical enterprises Low cost will inevitably bring about the quality and safety problems of drugs Second, it affects the supply of drugs According to a senior manager of a pharmaceutical company, in some cities in Zhejiang and Anhui, "second price negotiation" has led to the withdrawal of many drugs with large dosage and definite curative effect due to price problems For example, the "second negotiation" of Ningbo Chinese patent medicine requires a further 15% reduction on the basis of the provincial bidding price, and finally only 244 of the 1263 varieties involved in the bidding catalogue won the bid In addition, malicious bidding cannot be excluded All along, in the process of drug bidding, malicious bidding is not uncommon Earlier, a marketing staff of a pharmaceutical company told e pharmaceutical managers: "some pharmaceutical manufacturers won the bid with lower prices for the varieties they didn't want to make, just to let their competitors lose the market After winning the bid, if you do not want to supply at such a low price, and do not want to affect the national bidding price linkage, you will adopt the strategy of "bid rejection" This is also one of the reasons why some provinces often reject the bid after winning the bid, leading to the lack of medicine available in hospitals It is worth noting that the provincial and municipal quotations of multinational pharmaceutical enterprises are almost the same According to the catalogue, there are 10 and 12 products in the list of international pharmaceutical enterprises, most of which are almost the same as the provincial bidding price, and the price reduction is obvious The price of motimecorol ester capsule of Roche pharmaceutical is reduced from 601 yuan to 505.2 yuan; the price of lactulose oral solution of Korean and American drugs is reduced from 40.9 yuan to 31 yuan Second bargaining gradually becomes a new normal Is the bidding and purchasing system useless? Obviously, the controversial second bargaining has become more and more legitimate In February 2015, the general office of the State Council issued the guiding opinions on improving the centralized drug procurement in public hospitals (the opinions), which clearly states that "in the pilot cities of public hospital reform, it is allowed to purchase drugs by itself on the provincial centralized drug procurement platform with the city as the unit" The note is considered tacit "second bargaining" At that time, the pilot of comprehensive medical reform only included Jiangsu, Anhui, Fujian and Qinghai In 2016, the national health and Family Planning Commission began to increase the intensity of medical reform, increasing the number of pilot cities to 200 cities, which means that the "second bargaining" has been allowed by policies and gradually become a new normal Industry insiders believe that, in addition to the first low price theory, for pharmaceutical enterprises, the second bargaining means that they need to add some extra energy to deal with the new bargaining body; in addition, for the industry, the second bargaining will, to some extent, overhead the original bidding and procurement system, lose the function of the provincial bidding, and the provincial bidding platform may be in vain Moreover, the drug price system formed in the past may be gradually broken Attachment: list of drugs and enterprises with a decrease rate exceeding 50% of the bid price